Provided by Tiger Trade Technology Pte. Ltd.

Aclaris Therapeutics

3.26
+0.07002.19%
Post-market: 3.17-0.0900-2.76%17:43 EST
Volume:1.15M
Turnover:3.77M
Market Cap:353.21M
PE:-2.49
High:3.38
Open:3.19
Low:3.12
Close:3.19
52wk High:4.89
52wk Low:1.05
Shares:108.35M
Float Shares:72.65M
Volume Ratio:1.55
T/O Rate:1.59%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3077
EPS(LYR):-1.7085
ROE:-113.23%
ROA:-22.98%
PB:2.94
PE(LYR):-1.91

Loading ...

Aclaris Therapeutics to Present at Major Healthcare Conferences

Reuters
·
Feb 04

Aclaris Therapeutics to Participate in Two February Healthcare Conferences

GlobeNewswire
·
Feb 04

Aclaris Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
Jan 28

Aclaris Hair Loss Drug Shows Faster Results Than Pfizer's Drug

Benzinga_recent_news
·
Jan 28

Aclaris Therapeutics reports ‘positive’ results from ATI-2138

TIPRANKS
·
Jan 27

Aclaris Therapeutics Inc - to Initiate Phase 2B Trial for ATI-2138 in First Half of 2026

THOMSON REUTERS
·
Jan 27

Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)

GlobeNewswire
·
Jan 27

Aclaris Therapeutics Down Over 15%, on Pace for Largest Percent Decrease Since January 2024 -- Data Talk

Dow Jones
·
Jan 27

Aclaris Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
Jan 21

Aclaris Therapeutics Up Over 32%, On Track for Largest Percent Increase Since November 2024 -- Data Talk

Dow Jones
·
Jan 21

Aclaris Therapeutics Launches Phase 1b Trial of Bispecific Antibody ATI-052 in Atopic Dermatitis

Reuters
·
Jan 12

Aclaris Therapeutics Initiates Phase 1B Proof-of-Concept Trial in Atopic Dermatitis (Ad) With Its Novel Bispecific Antibody ATI-052

THOMSON REUTERS
·
Jan 12

Aclaris Therapeutics Inc - Top Line Results From Poc Trials Expected in H2 2026

THOMSON REUTERS
·
Jan 12

Aclaris Therapeutics Inc - to Initiate Phase 1B Trial in Asthma This Quarter

THOMSON REUTERS
·
Jan 12

BUZZ-U.S. STOCKS ON THE MOVE-United Airlines Holdings, Energy companies, Tesla

Reuters
·
Jan 07

BUZZ-U.S. STOCKS ON THE MOVE-Shake Shack, Arrowhead Pharmaceuticals, Lockheed Martin

Reuters
·
Jan 06

BUZZ-U.S. STOCKS ON THE MOVE-Alkermes, Ball Corp, NovaBridge

Reuters
·
Jan 06

Aclaris Therapeutics Says Phase 1 Trial of Dermatitis Therapy Candidate ATI-052 Shows 'Strong Safety' Profile

MT Newswires Live
·
Jan 06

BUZZ-Aclaris rises as inflammation drug shows promise in early trial

Reuters
·
Jan 06

Aclaris Therapeutics Inc: Expects Top Line Data From Both Trials in Second Half of 2026.

THOMSON REUTERS
·
Jan 06